Low-dose hypomethylating agents offer promising, well-tolerated disease control for low-risk myelodysplastic syndromes. Recent trials show decitabine achieves a 67% response rate versus 48% for azacitidine, frequently restoring transfusion independence. With a median overall survival of 33 months, low-dose therapy presents a valuable alternative for low-intermediate risk patients.